E-Learning Center
Join Our Network

Follow Imedex on Twitter

OncoFacts

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?






XXXConference NameXXX


 

5th ISC International Conference on Cancer Therapeutics

2 - 4 April 2009

Barcelona, Spain

THIS CONFERENCE HAS BEEN CANCELLED

 

 

 

 


 

 

 

 

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com